9.38 USD
▲+0.88+10.29%
盘后 9.25 0.00%
2026-09-16
市值
$97.42M
市盈率
—
EPS
-10.52
股息率
—
52 周区间
6.01 – 17.44
成交量
163.98K
Beta
1.59
目标价
33.17
52W 低 6.0152W 高 17.44
价格走势
公司简介
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ...